In previous papers we demonstrated that tetrabranched peptides containing the sequence of human neurotensin, NT4, are much more selective than native monomeric analogues for binding to different human cancer cells and tissues. We show here that the much higher binding of NT4 peptides, with respect to native neurotensin, to either cancer cell lines or human cancer surgical samples is generated by a switch in selectivity toward additional membrane receptors, which are specifically expressed by different human cancers. We demonstrate that the branched structure provides NT4 with ability to bind heparin and receptors belonging to the low density lipoprotein receptor (LDLR) family, known to be involved in cancer biology. Systematic modification ...
Background Neurotensin, originally isolated in 1973 has both endocrine and neuromodulator activity a...
The tetra-branched peptide NT4 selectively binds to different human cancer cells and tissues. NT4 sp...
Cancer is a worldwide health problem. Personalized treatment represents a future advancement for can...
In previous papers we demonstrated that tetrabranched peptides containing the sequence of human neur...
NT4 is a tetrabranched peptide containing four neurotensin sequences that selectively binds human ca...
The aim of this study was to demonstrate that oligo-branched peptides can be effective either for sp...
Receptors for endogenous regulatory peptides, like the neuropeptide neurotensin, are overexpressed i...
Nanoparticles have attracted much attention for their potential application as in vivo carriers of d...
0001] The instant invention refers to in vivo stable branched peptides derived from the sequence of ...
Despite recent advances in multimodal therapy, bladder cancer still ranks ninth in worldwide cancer ...
Cancer-selective tetra-branched peptides, named NT4, can be coupled to different functional units fo...
Background Neurotensin, originally isolated in 1973 has both endocrine and neuromodulator activity a...
The tetra-branched peptide NT4 selectively binds to different human cancer cells and tissues. NT4 sp...
Cancer is a worldwide health problem. Personalized treatment represents a future advancement for can...
In previous papers we demonstrated that tetrabranched peptides containing the sequence of human neur...
NT4 is a tetrabranched peptide containing four neurotensin sequences that selectively binds human ca...
The aim of this study was to demonstrate that oligo-branched peptides can be effective either for sp...
Receptors for endogenous regulatory peptides, like the neuropeptide neurotensin, are overexpressed i...
Nanoparticles have attracted much attention for their potential application as in vivo carriers of d...
0001] The instant invention refers to in vivo stable branched peptides derived from the sequence of ...
Despite recent advances in multimodal therapy, bladder cancer still ranks ninth in worldwide cancer ...
Cancer-selective tetra-branched peptides, named NT4, can be coupled to different functional units fo...
Background Neurotensin, originally isolated in 1973 has both endocrine and neuromodulator activity a...
The tetra-branched peptide NT4 selectively binds to different human cancer cells and tissues. NT4 sp...
Cancer is a worldwide health problem. Personalized treatment represents a future advancement for can...